1. Breast Cancer Statistics, 2022;Giaquinto;CA A Cancer J. Clin.,2022
2. Intrinsic Molecular Subtypes of HER2+ Breast Cancer;Prat,2017
3. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival;Miglietta;ESMO open,2022
4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol.,2020
5. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial;Hurvitz;Lancet,2023